Abstract
There are no generally accepted guidelines for the follow-up of cutaneous melanoma (CM), and there is an ongoing debate about the value of follow-up examinations. Some authors doubt whether early detection has any beneficial effect on patient survival and suggest that it may only prolong the patient’s period of suffering from the knowledge of having metastasis. A systematic review of the literature on early detection and resection of CM metastasis shows the following picture: (1) In in-transit metastasis and in regional node metastasis, the tumour volume of the metastatic nodules at the time of diagnosis is prognostically significant. Either the number of nodes involved in regional metastasis or the diameter of the largest node showed prognostic impact in different studies. Therefore, early detection seems to affect the cure rate in this stage of disease. (2) In distant metastasis, surgical resection of all recognisable metastases prolongs survival. This is true as long as only one organ system is involved and particularly if complete resection of all metastases can be achieved. Therefore, early detection contributes to prolongation of survival. We performed a follow-up study in 2008 prospectively documented consecutive patients with stage I–III cutaneous melanoma who presented for follow-up examination at the Department of Dermatology of the University of Tübingen from August 1996 to August 1998. Stage-appropriate follow-up examinations were carried out according to the German Society of Dermatology guidelines. A total of 3800 clinical examinations and 12 398 imaging techniques were documented: 62 second primary melanomas were detected in 46 patients and 233 disease recurrences in 112 patients during this time. Physical examination was responsible for the discovery of 50% of all recurrences, with the patient initially detecting the metastasis on self-examination in 17% of these cases. Technical examinations were responsible for the detection of the remaining 50%. In the primary tumour stages, 21% of all recurrences were discovered by lymph node sonography, the majority being classified as early detection. Among the recurrences, 48% were classified as early detection, and these patients had a significantly more favourable probability of recurrence-free survival than those with recurrences classified as late detection. The results of our study suggest that the follow-u schedule elaborated for cutaneous melanoma is suitable for the early detection of second primary melanomas and of early recurrences in approximately 5% patients during a 2-year follow-up period.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Anonymous (1995a) Conférence de consensus. Suivi des patients opérés d’un mélanome de stade I. Ann Dermatol Venereol 122:250–258.
Anonymous (1995b) Conférence de consensus. Suivi des patients opérés d’un mélanome de stade I. Paris, France, 30 March 1995. Ann Dermatol Venereol 122:250–391.
Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R (1987) Stage I–II melanoma: the value of metastatic work-up. Oncology 44:87–89.
Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet VA, Lota I, Bonerandi JJ (1995) Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 191:199–203.
Berman C, Reintgen D (1993) Radiologic imaging in malignant melanoma: a review. Semin Surg Oncol 9:232–238.
Blaheta HJ, Schittek B, Breuninger H, Maczey E, Kroeber S, Sotlar K, Ellwanger U, The-len MH, Rassner G, Bultmann B, Garbe C (1998) Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry Int J Cancer 79:318–323.
Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G (1995) Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 131:1394–1398.
Blum A, Dill-Miiller D (1998) Ultrasound of lymph nodes and the subcutis in dermatology. Hautarzt 49:942–949.
Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, Ariyan S (1993) Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11:638–643.
Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS (1995) Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 13:2104–2108.
Curry BJ, Smith MJ, Hersey P (1996) Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Res 6:45–54.
Curry BJ, Myers K, Hersey P (1998) Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 16:1760–1769.
Farthmann B, Eberle J, Krasagakis K, Gstottner M, Wang N, Bisson S, Orfanos CE (1998) RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 110:263–267.
Finck SJ, Giuliano AE, Morton DL (1983) LDH and melanoma. Cancer 51:840–843.
Garbe C (1996) Verlangertes Überleben bei fernmetastasiertem Melanom und der Einfluss von Behandlungen: Analyse des Krankheitsverlaufs von 22 Patienten mit einer Überlebenszeit von zwei Jahren und langer. Hautarzt 47:35–43.
Garbe C (1997) Epidemiologic des Hautkrebses. In: Garbe C, Dummer R, Kaufmann R, Tilgen W (eds) Dermatologische Onkologie. Springer, Berlin, Heidelberg, New York, pp 40–56.
Garbe C, Büttner P, Ellwanger U, Bröcker EB, Jung EG, Orfanos CE, Rassner G, Wolff HH (1995) Das Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft in den Jahren 1983–1993. Epidemiologische Entwicklungen und aktuelle therapeutische Versorgung des malignen Melanoms der Haut. Hautarzt 46:683–692.
Garbe C, Reusch M, Breuninger H, Dummer R, Hauschild A, Kaufmann R, Mensing HO, Meyer, Panizzon R, Schmockel C, Schofer H, Sebastian G, Soyer HP, Sterry W, Tilgen W, Volkenandt M (1998) Diagnostische und therapeutische Standards in der dermatologischen Onkologie. Hautarzt 48 [Suppl 1]:S13–S55.
Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W (1997) Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15:2818–2825.
Goerz G, Schulte BR, Roder K, Schoppe WD, Munchhoff C, Jungblut RM (1986) Malignes Melanom. Welche Untersuchungen sind fur Staging und Verlaufskontrollen sinnvoll Dtsch Med Wochenschr 111:1230–1233.
Guo HB, Stoffel WB, Bierwirth T, Mezger J, Klingmiiller D (1995) Clinical significance of serum SI00 in metastatic malignant melanoma Eur J Cancer [A] 31:1898–1902.
Haffner AC, Garbe C, Burg G, Biittner P, Orfanos CE, Rassner G (1992) The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66:856–861.
Hanekom GS, Johnson CA, Kidson SH (1997) An improved and combined reverse tran- scription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood. Melanoma Res 7:111–116.
Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344.
Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E (1999) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155–161.
Henze G, Dummer R, Joller JH, Boni R, Burg G (1997) Serum SI00 - a marker for disease monitoring in metastatic melanoma. Dermatology 194:208–212.
Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS (1998) Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 39:451–463.
Iscoe N, Kersey P, Gapski J, Osoba D, From L, DeBoer G, Quirt I (1987) Predictive value of staging investigations in patients with clinical stage I malignant melanoma. Plast Reconstr Surg 80:233–239.
Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, Quirt IC (1985) The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 72:614–617.
Khansur T, Sanders J, Das SK (1989) Evaluation of staging workup in malignant melanoma. Arch Surg 124:847–849.
Kuvshinoff BW, Kurtz C, Coit DG (1997) Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 4:252–258.
National Institutes of Health (1992) Diagnosis and treatment of early melanoma. NIH Consensus Development Conference, 27–29 January 1992. Consensus Statement 10:1–25.
National Institutes of Health (1992) NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 268:1314–1319.
Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C (1994) Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Stand 1993/94. Hautarzt 45:285–291.
Prayer L, Winkelbauer H, Gritzmann N, Winkelbauer F, Helmer M, Pehamberger H (1990) Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma. Eur J Cancer 26:827–830.
Provost N, Marghoob AA, Kopf AW, DeDavid M, Wasti Q, Bart RS (1997) Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol 36:711–720.
Rümke P, van-Everdingen JE (1992) Consensus on the management of melanoma of the skin in The Netherlands. Dutch Melanoma Working Party Eur J Cancer 28:600–604.
Rinne D, Baum RP, Hor G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82:1664–1671.
Salopek TG, Marghoob AA, Slade JM, Rao B, Rigel DS, Kopf AW, Bart RS (1995) An estimate of the incidence of malignant melanoma in the United States. Based on a survey of members of the American Academy of Dermatology. Dermatol Surg 21:301–305.
Schweizerische Gesellschaft fur Dermatologie und Venerologie (1993) Das primare ma- ligne Melanom der Haut. Bull Med Suisse 74:1021–1024.
Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, DeConti R, Cruse CW, Berman C, Fenske NA, Lyman GH, Reintgen DS (1998) Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 280:1410–1415.
Stadelmann WK, Rapaport DP, Soong SJ, Reintgen DS, Buzaid AC, Balch CM (1998) Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Quality Medical Publishing, St Louis, pp 11–50.
Steinert HC, Huch BR, Buck A, Böni R, Berthold T, Marincek B, Burg G, von-Schulthess GK (1995) Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-d-glucose Radiology 195:705–709.
Terhune MH, Swanson N, Johnson TM (1998) Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 134:569–572.
Wagner JD, Schauwecker D, Hutchins G, Coleman JJ (1997) Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64:181–189.
Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR (1995) Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274:1703–1705.
Wittekind C, Wagner G (1997) TNM Klassifikation maligner Tumoren, 5th edn. Springer, Berlin Heidelberg New York.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Garbe, C. (2002). A Rational Approach to the Follow-up of Melanoma Patients. In: Dummer, R., Nestle, F.O., Burg, G. (eds) Cancers of the Skin. Recent Results in Cancer Research, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59410-6_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-59410-6_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63969-2
Online ISBN: 978-3-642-59410-6
eBook Packages: Springer Book Archive